<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang P</submitter><funding>National Natural Science Foundation of China</funding><pagination>e01900-20</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7848972</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>65(2)</volume><pubmed_abstract>Despite excellent bactericidal effect, dosing adjustment of polymyxin B for patients with renal insufficiency and polymyxin B-related nephrotoxicity is still a major concern to clinicians. The aim of this study was to compare the population pharmacokinetics (PK) properties of polymyxin B in Chinese patients with different renal functions and to investigate the relationship between PK parameters and polymyxin B-related acute kidney injury (AKI). A total of 37 patients with normal renal function (creatinine clearance ≥ 80 ml/min) and 33 with renal insufficiency (creatinine clearance &lt; 80 ml/min) were included. In the two-compartment population PK models, the central compartment clearance (CL) (2.19 liters/h versus 1.58 liters/h; P &lt; 0.001) and intercompartmental clearance (Q) (13.83 liters/h versus 10.28 liters/h; P &lt; 0.001) values were significantly different between the two groups. The simulated values for AUC across 24 h at steady state (AUCss,24h) for patients with normal renal function were higher than those for patients with renal insufficiency. However, renal dosing adjustment of polymyxin B seemed not to be necessary. In addition, during the treatment, AKI occurred in 23 (32.86%) patients. The polymyxin B AUCss,24h in patients with AKI was significantly higher than that in patients without AKI (108.66 ± 70.10 mg · h/liter versus 66.18 ± 34.79 mg · h/liter; P = 0.001). Both the receiver operating characteristic (ROC) curve and logistic regression analysis showed that an AUCss,24h of >100 mg · h/liter was a good predictor for the probability of nephrotoxicity.</pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pubmed_title>Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.</pubmed_title><pmcid>PMC7848972</pmcid><funding_grant_id>81803638</funding_grant_id><funding_grant_id>81703799</funding_grant_id><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Feng M</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Sun T</pubmed_authors><pubmed_authors>Pei H</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.</name><description>Despite excellent bactericidal effect, dosing adjustment of polymyxin B for patients with renal insufficiency and polymyxin B-related nephrotoxicity is still a major concern to clinicians. The aim of this study was to compare the population pharmacokinetics (PK) properties of polymyxin B in Chinese patients with different renal functions and to investigate the relationship between PK parameters and polymyxin B-related acute kidney injury (AKI). A total of 37 patients with normal renal function (creatinine clearance ≥ 80 ml/min) and 33 with renal insufficiency (creatinine clearance &lt; 80 ml/min) were included. In the two-compartment population PK models, the central compartment clearance (CL) (2.19 liters/h versus 1.58 liters/h; P &lt; 0.001) and intercompartmental clearance (Q) (13.83 liters/h versus 10.28 liters/h; P &lt; 0.001) values were significantly different between the two groups. The simulated values for AUC across 24 h at steady state (AUCss,24h) for patients with normal renal function were higher than those for patients with renal insufficiency. However, renal dosing adjustment of polymyxin B seemed not to be necessary. In addition, during the treatment, AKI occurred in 23 (32.86%) patients. The polymyxin B AUCss,24h in patients with AKI was significantly higher than that in patients without AKI (108.66 ± 70.10 mg · h/liter versus 66.18 ± 34.79 mg · h/liter; P = 0.001). Both the receiver operating characteristic (ROC) curve and logistic regression analysis showed that an AUCss,24h of >100 mg · h/liter was a good predictor for the probability of nephrotoxicity.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2025-04-22T08:16:10.278Z</modification><creation>2022-02-10T20:43:29.28Z</creation></dates><accession>S-EPMC7848972</accession><cross_references><pubmed>33168613</pubmed><doi>10.1128/AAC.01900-20</doi><doi>10.1128/aac.01900-20</doi></cross_references></HashMap>